BioSpace News Archive

Excellent Safety Profile and Improvements in Clinically Relevant Secondary Endpoints (Endoscopy and Histology) Support Further Development by a Partner

Rocket’s Largest Lentiviral Pipeline Opportunity with an Estimated Prevalence of 3,000 to 8,000 Patients in the U.S. and EU

VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on Tuesday, November 5, 2019.

Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2019 earnings release and conference call.

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced that promising preclinical data from two of its gene therapy-focused subsidiaries – Adrenas Therapeutics and Aspa Therapeutics – will be presented at the European Society of Gene and Cell Therapy (ESGCT) Conference, occurring in Barcelona from October 22 to 25

Ovizio Imaging Systems, a company providing an innovative microscopic imaging technology to the bioprocessing market, today announces the execution of supply agreements with Celgene Corporation for the automation of certain engineered T cell manufacturing processes.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected for a podium presentation at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, taking place November 6-10, 2019, in National Harbor, MD.

The market will accelerate at a CAGR of over 6% between 2019-2023